Givaudan

FY25: Our conservative view proved right

29/01/26 -"Givaudan’s top-line performance was approximately in line with expectations; however, this was insufficient due to higher-than-anticipated costs. These costs significantly impacted the gross ..."

PDF page sample
Pages
51
Language
English
Published on
29/01/26
Download
You may also be interested by these reports :
29/01/26
Givaudan’s top-line performance was approximately in line with expectations; however, this was insufficient due to higher-than-anticipated costs. ...
28/01/26
We have revised our FY25 EPS upward, primarily reflecting management guidance pointing to higher at-equity earnings from Wintershall Dea. Our FY26 ...
28/01/26
Wacker’s preliminary FY25 results remain uninspiring, with earnings falling short of already conservative market expectations. While sales remained ...
28/01/26
We have reduced our FY25/26 estimates, with sales now forecast at €9.0bn/€9.1bn (vs. €9.7bn/€9.9bn previously), and adjusted EBITDA at €1.3bn/€1.3bn ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO